trial

One Year Drug Treatment in First-Episode Schizophrenia

NCTId NCT00159081
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 159 (actual)
Sponsored by Heinrich-Heine University, Duesseldorf
Primary completion 2005-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
159 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2000-11
Primary completion
2005-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Heinrich-Heine University, DuesseldorfLead Sponsor
German Federal Ministry of Education and ResearchCollaborator
German Research Network On SchizophreniaCollaborator
Janssen-Cilag Farmaceutica Ltda.Collaborator
University of BonnCollaborator
Humboldt-Universität zu BerlinCollaborator
University of MünchenCollaborator
University of GöttingenCollaborator
University of CologneCollaborator
Mainz UniversityCollaborator
University Hospital TuebingenCollaborator
Universität Duisburg-EssenCollaborator
University of MannheimCollaborator
University of JenaCollaborator
Martin-Luther-Universität Halle-WittenbergCollaborator
RWTH Aachen UniversityCollaborator
University of WuerzburgCollaborator

Investigators

1
Wolfgang Gaebel, ProfessorStudy Chair

Sites

1 total
Düsseldorf, Germany

Facts & assertions

4 sourced
Enrollment
159
Phase
PHASE4
Primary Completion Date
2005-06
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Heinrich-Heine University, Duesseldorf
company
collaborator
German Federal Ministry of Education and Research
company
German Research Network On Schizophrenia
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Wolfgang Gaebel, Professor
person